A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Inclusion Criteria

• •All Parts: Participants must have disease that is relapsed, refractory, or intolerant to standard of care. Participants must have histologically or cytologically confirmed metastatic malignancy.
• •Participants must have one of the following tumor types:
• •* Parts A and B: Participants must have metastatic or unresectable cutaneous melanoma.
• •* Part C: Participants must have one of the following tumor types:
• •* Cutaneous Melanoma
• •* Non-small Cell Lung Cancer (NSCLC)
• •* Colorectal Cancer (CRC)
• •* Pancreatic Cancer
• •* Mesothelioma
• •A pre-treatment biopsy or submission of archival tissue is required
• •For participants with cutaneous melanoma
• •* Must have been previously treated with an anti-programmed death-1 (anti-PD-1) or anti-programmed death ligand-1 (anti-PD-L1) agent given alone or with other therapies.
• •* Participants with a targetable BRAF mutation must have been treated with, been intolerant of, or been deemed ineligible to receive treatment with BRAF/MEK targeted therapy prior to study entry.
• •Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
• •Measurable disease per RECIST v1.1 at baseline